Depomed Files NDA; Second Quarter Earnings on Thursday for More Info

Depomed Inc. (NASDAQ:DEPO) announced last night that it has submitted a New Drug Application to the FDA for  Serada, the company’s extended release formulation of gabapentin for treating menopausal hot flashes. If approved, the company says the drug has a potential market of 32 million women in the U.S., many of whom may prefer a non-hormonal, extended release treatment option. Depomed has three marketed products and two in development and has seen consistent revenue growth over the last three years. The company also reported last week that its Phase III study of Gralise showed positive results in treating pain for patients with postherpetic neuralgia. (more…)